Abstract: Due to poor prognosis and low survival rate, pancreatic cancer remains a major threaten to human health. And cancer-associated thrombosis is one of the main factors infl uencing the prognosis in pancreatic cancer patients. There have been an increasing number of studies on low-molecular-weight heparin reducing the incidence of venous thrombosis, and even improving the survival of cancer patients. In this review, we briefl y summarize the progress of low-molecular-weight heparin treatment on pancreatic cancer patients and the molecular mechanism involved．